Possible inhibitory effect of diazepam on the metabolism of zotepine, an antipsychotic drug

Psychopharmacology

Volumn 127, Issue 4, 1996, Pages 311-314

  Kondo, Tsuyoshi ^a   Tanaka, Osamu ^a   Otani, Koichi ^a   Mihara, Kazuo ^a   Tokinaga, Noboru ^a   Kaneko, Sunao ^a   Chiba, Kan ^b   Ishizaki, Takashi ^b  

^a HIROSAKI UNIVERSITY   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

CYP2C19; Diazepam; Metabolism; Smoking; Zotepine

Indexed keywords

CYTOCHROME P450; DIAZEPAM; NEUROLEPTIC AGENT; ZOTEPINE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOTRANSFORMATION; CLINICAL TRIAL; COMPETITIVE INHIBITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; MENTAL PATIENT; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SMOKING; VOLUNTEER;

ADULT; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; DIAZEPAM; DIBENZOTHIEPINS; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; SMOKING;

EID: 0029858354     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050091     Document Type: Article

References (21)

1. Andersson T, Miners JO, Veronese ME, Birkett DJ (1994) Diazepam metabolism by human liver microsomes is mediated by both mephenytoin hydroxylase and CYP3A isoforms. Br J Clin Pharmacol 38:131-137
2. Barnas C, Stuppäck CH, Miller C, Haring C, Sperner-Unterweger B, Fleischhacker WW, (1992) Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol. Int Clin Psychopharmacol 7:23-27
3. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villen T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 45:348-355
4. Bock KW, Schrenk D, Adelheid F, Griese E-U, Mörike K, Brockmeier D, Eichelbaum M (1994) The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 4:209-218
5. Dahl-Puustinen M-L, Liden A, Alm C, Nordin C, Bertilsson L (1989) Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 46:78-81
6. Ereshefsky L, Jann MW, Saklad SR, Davis CM, Richards AL, Burch NR (1985) Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 20:329-352
7. Fleischhacker WW, Barnas C, Stuppäck CH, Unterweger B, Miller C, Hinterhuber H (1989) Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull 25:97-100
8. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou H-H, Zhou B-J, Liao C-L, Zhang L-M (1989) Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46:198-207
9. Kondo T, Otani K, Ishida M, Mihara K, Tanaka O, Kaneko S, Fukushima Y (1993) A study of the therapeutic spectrum of a fixed-doses of zotepine and its relationship with serum concentrations of the drug. Hum Psychopharmacol 8:133-139
10. Kondo T, Otani K, Ishida M, Tanaka O, Kaneko S, Fukushima Y (1994) Adverse effects of zotepine and their relationship to serum concentrations of the drug and prolactin. Ther Drug Monit 16:120-124
11. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. Acta Psychiatr Scand 76 [Suppl. 334]: 11-100
12. LLerena A, Dahl M-L, Ekqvist B, Bertilsson L (1992) Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 14:261-264
13. Louis L, Rowe H, Bosomworth JC, Tenbarge JB, Bergström RF (1989) The effects of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 43:412-419
14. Miller DD, Kelly MW, Perry PJ, Coryell WH (1990) The influence of cigarette smoking on haloperidol pharmacokinetics. Biol Psychiatry 28:529-531
15. Noda K, Suzuki A, Okui H, Noguchi H, Nishiura M, Nishiura N (1979) Pharmacokinetics and metabolism of 2-chloro-11-(2-dimethylaminoethoxy)-dibenzo [b, f] thiepine (Zotepine) in rat, mouse, dog and man. Arzneimittelforschung 29:1595-1600
16. Otani K, Kondo T, Kaneko S, Hirano T, Mihara K, Fukushima Y (1993) Steady-state serum kinetics of zotepine. Hum Psychopharmacol 7:331-336
17. Sohn D-L, Kusaka M, Ishizaki T, Shin S-G, Jang I-G, Shin J-G, Chiba K (1992) Incidence of S-mephenytoin hydroxylation deficiency in a korean population and the interphenotypic differences in diazepam pharmacokinetics. Clin Pharmacol Ther 52:160-169
18. Tanaka O, Kondo T, Kaneko S, Mihara K, Otani K, Tokinaga N (1996) A method for rapid determination of zotepine by gas chromatography-mass spectrometry. Ther Drug Monit 18:294-296
19. Uchida S, Honda F, Otsuka M, Sato Y, Mori J, Ono T, Hitomi M (1979) Pharmacological study of [2-chloro-11-(2-dimethylaminoethoxy) dibenzo [b, f] thiepine] (Zotepine), a new neuroleptic drug. Arzneimittelforschung 29:1588-1594
20. von Bahr C, Movin G, Nordin C, Liden A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sjöqvist F (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation. Clin Pharmacol Ther 49:234-240
21. Yamawaki S (1987) Profiles of clinical efficacy and pharmacological action of zotepine. Pharmacopsychiatry 20:4-7